| Date |
Title |
| 6/10/2013 |
Stemline Therapeutics’ SL-401 Receives Orphan Drug Designation for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) |
|
| 5/31/2013 |
Stemline Therapeutics to Present at the Jefferies 2013 Global Healthcare Conference |
|
| 5/30/2013 |
Stemline Therapeutics Announces Presentations at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting |
|
| 5/23/2013 |
Stemline Therapeutics Announces Exercise of Option to Purchase Additional Shares |
|
| 5/22/2013 |
Stemline Therapeutics Announces Closing of $60 Million Public Offering of Common Stock |
|
| 5/16/2013 |
Stemline Therapeutics Prices $60 Million Public Offering of Common Stock |
|
| 4/25/2013 |
Stemline Therapeutics to Present at the 12th Annual Needham Healthcare Conference on May 1, 2013 |
|
| 4/8/2013 |
Stemline Therapeutics, Inc. Announces Presentation of SL-401 Preclinical Efficacy in Multiple Myeloma at the 14th International Myeloma Workshop in Kyoto, Japan |
|
| 4/1/2013 |
Stemline Therapeutics Reports Year-End 2012 Financial Results |
|
| 3/12/2013 |
Stemline Therapeutics to Present at the 25th Annual Roth Conference on March 20, 2013 |
|
| 2/27/2013 |
Stemline Therapeutics to Present at the Cowen and Company 33rd Annual Health Care Conference on March 4, 2013 |
|
| 2/12/2013 |
Stemline Therapeutics to Present at Leerink Swann and Company Global Healthcare Conference |
|
| 2/7/2013 |
Stemline Therapeutics, Inc. to Present at BIO CEO & Investor Conference on February 11th |
|
| 1/31/2013 |
Stemline Therapeutics, Inc. Announces Closing of Initial Public Offering |
|
| 1/29/2013 |
Stemline Therapeutics, Inc. Announces Exercise of Over-Allotment Option |
|
| 1/28/2013 |
Stemline Therapeutics, Inc. Announces Pricing of Initial Public Offering of 3,317,644 Shares of Common Stock |
|
| 1/7/2013 |
Stemline Therapeutics’ Lead Clinical Candidate, SL-401, Induces Another Complete Response in a Patient with a Drug-Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm |
|
| 12/7/2012 |
Stemline Therapeutics, Inc. Announces Presentations of SL-401 Updated Clinical Trial Results in Acute Myeloid Leukemia (AML) and Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) and SL-101 Preclinical Efficacy Data Against Hodgkin’s Lymphoma at the 54th Annual Meeting of the American Society of Hematology (ASH) |
|
| 11/8/2012 |
Stemline Therapeutics’ Lead Clinical Candidate SL-401 Induces a Complete Response in a Patient with a Drug-Refractory Plasmacytoid Dendritic Cell Neoplasm |
|
| 4/18/2012 |
Stemline Therapeutics Announces Two Presentations of Direct Injection Synthetic Peptide Vaccine for Brain Cancer, Now Being Developed as SL-701, at the Annual Meeting of the American Association of Cancer Research (AACR) |
|
| 4/3/2012 |
Stemline Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering |
|
| 3/15/2012 |
Stemline Therapeutics Appoints Kevin Buchi, Former CEO of Cephalon, to its Board of Directors |
|
| 1/9/2012 |
Stemline Therapeutics, Inc. Names Eric K. Rowinsky, M.D. Chief Medical Officer and Head of Research and Development |
|
| 12/12/2011 |
Stemline Therapeutics, Inc. to Present at the Oppenheimer 22nd Annual Healthcare Conference |
|
| 12/8/2011 |
Stemline Therapeutics, Inc. Announces Two Poster Presentations of SL-401 Efficacy Data Against Lymphoid Cancers at the 53rd Annual Meeting of the American Society of Hematology (ASH) |
|
| 6/2/2011 |
Stemline Therapeutics, Inc. Announces Oral Presentation of Positive Phase I/II Trial Results with Novel Brain Cancer Vaccine at the American Society of Clinical Oncology (ASCO) 2011 Annual Meeting |
|
| 3/9/2011 |
Stemline Therapeutics Receives Orphan Drug Designation for SL-401 for the Treatment of Acute Myeloid Leukemia |
|
| 2/23/2011 |
Stemline Therapeutics Licenses Phase I/II Brain Cancer Vaccine - Shows Promise in Clinical Trial Conducted at University of Pittsburgh |
|
| 12/1/2010 |
Stemline Therapeutics, Inc. Announces Presentations of SL-401 Clinical and Pre-Clinical Efficacy at the 52nd Annual Meeting of the American Society of Hematology (ASH) |
|
| 12/4/2009 |
Stemline Therapeutics Announces Poster Presenting in vivo and Anti-Cancer Stem Cell Activity of SL-401 against Chronic Myeloid Leukemia (CML) at the 51st Annual Meeting of the American Society of Hematology (ASH) |
|
| 11/30/2009 |
Stemline Therapeutics Expands Clinical Oncology Program Directed at Cancer Stem Cells With Addition of MD Anderson Cancer Center |
|
| 4/9/2008 |
Stemline Therapeutics raises $12.5 million |
|
| 3/7/2007 |
Stemline Therapeutics In-Licenses Phase I Oncology Compound |
|
| 9/29/2006 |
Stemline is awarded a National Institutes of Health STTR grant |
|
| 1/17/2005 |
Stemline licenses high throughput drug discovery technology from University of Cambridge |
|
